Most importantly, it has been demonstrated that the recovery of TRIM8 expression in ccRCC-derived cell lines was able to induce a significant p53-dependent reduction in the proliferation rate, making cancer cells sensitive to different chemotherapy drugs as Nutlin-3, Cisplatin, Axitinib and Sorafenib [56]. Here, TRIM8 is linked to cancer.